|
POROKERATOSIS 9, MULTIPLE TYPES
|
0.700 |
GeneticVariation
|
disease |
UNIPROT |
Genomic variations of the mevalonate pathway in porokeratosis.
|
26202976 |
2015 |
|
Osteoporosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
From January 2014 to March 2018, a retrospective study of 88 patients with spondylolisthesis and osteoporosis treated with minimally invasive transforaminal lumbar interbody fusion (MIS-TLIF) using the conventional pedicle screw (CPS group, n = 52) and the fenestrated pedicle screw (FPS group, n = 36) was performed with a follow-up of 30 months (range, 10-58 months).
|
31279300 |
2019 |
|
Osteoporosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Association of farnesyl diphosphate synthase polymorphisms and response to alendronate treatment in Chinese postmenopausal women with osteoporosis.
|
24534219 |
2014 |
|
Osteoporosis
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Our study showed a strong association between bone mineral density and polymorphisms in the FDPS gene, and a borderline association with LRP5 and SOST polymorphisms in postmenopausal Romanian women with osteoporosis.No association was found for VKORC1.
|
31774873 |
2019 |
|
Malignant Neoplasms
|
0.050 |
GeneticVariation
|
group |
BEFREE |
Sixteen genes have been associated with cancer, with five specifically associated with prostate cancer (BTG2, IGFBP3, SIRT1, MXI1, and FDPS).
|
24713434 |
2014 |
|
Primary malignant neoplasm
|
0.050 |
GeneticVariation
|
group |
BEFREE |
Sixteen genes have been associated with cancer, with five specifically associated with prostate cancer (BTG2, IGFBP3, SIRT1, MXI1, and FDPS).
|
24713434 |
2014 |
|
Alzheimer's Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Replication trials in five independent European samples detected associations of variants within HMGCS2, FDPS, NPC2, or ABCG1 with AD in some samples (P = 0.05 to P = 0.005).
|
17387528 |
2007 |
|
Alzheimer's Disease
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
Analysis of single nucleotide polymorphisms in the hFPPS gene and mRNA levels in autopsy-confirmed AD subjects was undertaken, and a genetic link between hFPPS and phosphorylated tau (P-Tau) levels in the human brain was identified.
|
24911527 |
2014 |
|
Malignant neoplasm of prostate
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
To determine if a higher sensitivity to bisphosphonates could in part explain the development of ONJ, the segregation of A/C rs2297480 polymorphism of gene encoding for the farnesyl pyrophosphate synthase (FDPS) with ONJ was evaluated in a cohort of 68 Caucasian patients treated with zoledronic acid for multiple myeloma and metastatic mammary and prostate cancer.
|
21196316 |
2011 |
|
Prostate carcinoma
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
To determine if a higher sensitivity to bisphosphonates could in part explain the development of ONJ, the segregation of A/C rs2297480 polymorphism of gene encoding for the farnesyl pyrophosphate synthase (FDPS) with ONJ was evaluated in a cohort of 68 Caucasian patients treated with zoledronic acid for multiple myeloma and metastatic mammary and prostate cancer.
|
21196316 |
2011 |
|
Facial Pain
|
0.020 |
GeneticVariation
|
phenotype |
BEFREE |
Facial Pain Scale Revised (FPS-R) and Face, Leg, Activity, Cry, Consolability (FLACC) scores were used to evaluate pain and anxiety before, during and after procedure.
|
28190665 |
2017 |
|
Multiple Myeloma
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
To determine if a higher sensitivity to bisphosphonates could in part explain the development of ONJ, the segregation of A/C rs2297480 polymorphism of gene encoding for the farnesyl pyrophosphate synthase (FDPS) with ONJ was evaluated in a cohort of 68 Caucasian patients treated with zoledronic acid for multiple myeloma and metastatic mammary and prostate cancer.
|
21196316 |
2011 |
|
Familial (FPAH)
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here, we performed massively parallel sequencing and exonic CNV screening of 12 isoprenoid genes in 134 index PK patients (61 familial and 73 sporadic) and identified causal mutations in three novel genes (PMVK, MVD, and FDPS) in addition to MVK in the mevalonate pathway.
|
26202976 |
2015 |
|
Infectious Otitis Media
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In children with AOM (n = 201), pain was assessed by parents as moderate/severe in 65% via interview; 90% with the FPS-R; and 91% with the FLACC Scale (P < 0.001).
|
30572868 |
2018 |
|
POROKERATOSIS 9, MULTIPLE TYPES
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Mutations in the mevalonate pathway genes in Chinese patients with porokeratosis.
|
27422687 |
2016 |
|
POROKERATOSIS 9, MULTIPLE TYPES
|
0.700 |
Biomarker
|
disease |
GENOMICS_ENGLAND |
Genomic variations of the mevalonate pathway in porokeratosis.
|
26202976 |
2015 |
|
POROKERATOSIS 9, MULTIPLE TYPES
|
0.700 |
Biomarker
|
disease |
CTD_human |
|
|
|
|
Porokeratosis
|
0.110 |
Biomarker
|
disease |
HPO |
|
|
|
|
Porokeratosis
|
0.110 |
Biomarker
|
disease |
BEFREE |
Mutation of four genes in this pathway, including mevalonate kinase, phosphomevalonate kinase, mevalonate diphosphate decarboxylase and farnesyl diphosphate synthase, have demonstrated to be responsible for porokeratosis (PK).
|
28765912 |
2017 |
|
Squamous cell carcinoma
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Pruritus
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Photosensitivity of skin
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
FPS-1 cells showed the same morphological and immunophenotypical characteristics as the primary tumor.
|
17094458 |
2006 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
To test the combined inhibition of RAGE in both tumor cell-intrinsic and non-tumor cells of the microenvironment, we performed in vivo treatment of xenografted tumors with FPS-ZM1 (1 mg/kg, two times per week).
|
27669433 |
2017 |
|
Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
A slow dissociation inhibition pattern and a noncompetitive allosteric binding mode were found, and cellular mechanism-of-action studies showed that these inhibitors inhibit tumor cell growth primarily by inhibiting <i>Hs</i>FPPS, leading to downregulation of Ras prenylation and cell apoptosis.
|
31725297 |
2019 |